Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-3.21 Insider Own3.46% Shs Outstand40.96M Perf Week2.02%
Market Cap185.96M Forward P/E- EPS next Y-1.36 Insider Trans4.09% Shs Float39.54M Perf Month3.18%
Income-76.66M PEG- EPS next Q-0.33 Inst Own50.08% Short Float5.79% Perf Quarter-40.03%
Sales3.50M P/S53.13 EPS this Y29.96% Inst Trans14.04% Short Ratio3.18 Perf Half Y-6.78%
Book/sh-0.32 P/B- EPS next Y23.14% ROA-119.62% Short Interest2.29M Perf Year0.89%
Cash/sh1.53 P/C2.97 EPS next 5Y- ROE-1555.11% 52W Range2.83 - 9.01 Perf YTD-9.38%
Dividend Est.- P/FCF- EPS past 5Y38.92% ROI-578.82% 52W High-49.61% Beta1.58
Dividend TTM- Quick Ratio5.61 Sales past 5Y-15.07% Gross Margin13.31% 52W Low60.42% ATR (14)0.32
Dividend Ex-Date- Current Ratio5.61 EPS Y/Y TTM8.58% Oper. Margin-1442.63% RSI (14)49.87 Volatility6.47% 6.15%
Employees84 Debt/Eq- Sales Y/Y TTM227.72% Profit Margin-2190.26% Recom1.00 Target Price16.70
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-114.59% Payout- Rel Volume1.11 Prev Close4.51
Sales Surprise-100.00% EPS Surprise-125.99% Sales Q/Q- EarningsMay 15 BMO Avg Volume718.94K Price4.54
SMA204.33% SMA50-8.57% SMA200-12.24% Trades Volume799,358 Change0.67%
Date Action Analyst Rating Change Price Target Change
May-30-24Initiated Stifel Buy $21
Nov-11-20Upgrade Cantor Fitzgerald Neutral → Overweight $4
Sep-18-20Initiated B. Riley FBR Buy $5
Feb-10-20Initiated SVB Leerink Outperform $6
Dec-10-19Resumed Cantor Fitzgerald Neutral $2 → $4
Aug-15-19Downgrade Maxim Group Buy → Hold
Aug-12-19Downgrade Cantor Fitzgerald Overweight → Neutral $29 → $2
Jul-26-19Downgrade Mizuho Buy → Neutral $17 → $4
Jun-27-19Initiated Mizuho Buy
Oct-12-18Initiated Mizuho Buy $17
Jun-03-24 07:30AM
May-28-24 07:30AM
May-16-24 03:01AM
May-15-24 12:53PM
07:43AM Loading…
May-07-24 07:30AM
May-03-24 11:19AM
Apr-23-24 02:04PM
Apr-22-24 05:58PM
04:27PM Loading…
Apr-01-24 08:30AM
Mar-19-24 06:53AM
Mar-18-24 07:30AM
Mar-05-24 07:30AM
Feb-15-24 05:52AM
Feb-01-24 04:05PM
Jan-08-24 07:30AM
Dec-15-23 07:30AM
Nov-27-23 07:30AM
Nov-17-23 10:09AM
04:29AM Loading…
Nov-14-23 04:29AM
Nov-13-23 12:23PM
Nov-01-23 07:30AM
Sep-26-23 07:30AM
Sep-12-23 12:48PM
Sep-07-23 07:30AM
Aug-30-23 07:30AM
Aug-11-23 07:41AM
Aug-08-23 08:27AM
Jul-28-23 07:30AM
Jul-19-23 08:30AM
Jul-07-23 08:30AM
Jul-03-23 08:45AM
Jun-09-23 07:30AM
Jun-01-23 07:30AM
May-30-23 08:00AM
May-25-23 12:27AM
May-22-23 07:30AM
May-16-23 09:00AM
May-13-23 08:15AM
May-11-23 07:54AM
Apr-18-23 07:15AM
Apr-10-23 07:30AM
Mar-31-23 06:22AM
Mar-29-23 07:30AM
Mar-24-23 07:30AM
Mar-16-23 07:30AM
Mar-14-23 07:30AM
Nov-14-22 07:30AM
Nov-08-22 02:28PM
Nov-03-22 12:44PM
Oct-19-22 07:30AM
Oct-04-22 07:30AM
Sep-22-22 07:30AM
Sep-13-22 07:30AM
Sep-08-22 08:48AM
Aug-11-22 07:30AM
Jul-20-22 07:30AM
Jun-24-22 10:08AM
Jun-13-22 01:27PM
Jun-10-22 03:30PM
Jun-08-22 01:21PM
Jun-06-22 02:04PM
Jun-01-22 02:25PM
May-31-22 02:27PM
May-25-22 02:29PM
May-23-22 03:32PM
May-19-22 03:02PM
May-18-22 03:12PM
May-17-22 09:27AM
May-13-22 07:30AM
May-12-22 02:47PM
May-11-22 02:28PM
May-10-22 02:36PM
May-06-22 03:48PM
May-04-22 07:30AM
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alland LeilaDirectorMay 16 '24Buy4.7111,00051,79982,857May 20 08:30 AM
Charles Faith L.DirectorApr 26 '24Buy3.287,55024,76478,323Apr 29 08:30 AM
Seshadri VishwasChief Executive OfficerApr 25 '24Buy3.2010,00032,000538,260Apr 29 08:30 AM
O'Malley Brendan M.SVP, General CounselApr 25 '24Buy3.248,60027,864188,718Apr 26 08:30 AM
Vazzano Joseph WalterChief Financial OfficerApr 25 '24Buy3.145,60817,609233,868Apr 26 08:30 AM
Seshadri VishwasChief Executive OfficerFeb 06 '24Buy4.3920,00087,800528,260Feb 07 08:30 AM
Alvino MarkDirectorJan 17 '24Sale5.117,08436,19962,816Jan 22 04:30 PM
Seshadri VishwasChief Executive OfficerSep 27 '23Buy4.0720,00081,400521,731Sep 29 07:30 AM
Charles Faith L.DirectorSep 27 '23Sale4.918,33040,92470,773Sep 29 04:30 PM
Alland LeilaDirectorSep 27 '23Sale3.907,24628,27071,857Sep 29 04:30 PM
Alvino MarkDirectorSep 27 '23Sale3.916,31624,72469,900Sep 29 04:30 PM
Silverstein Christine BerniDirectorSep 27 '23Sale3.916,33024,72187,884Sep 29 04:30 PM
Amoroso MichaelDirectorSep 27 '23Sale3.915,50821,542108,957Sep 29 04:30 PM
Amoroso MichaelDirectorSep 20 '23Sale3.903271,275114,465Sep 22 04:05 PM
Vazzano Joseph WalterChief Financial OfficerSep 19 '23Buy3.823,00011,458238,179Sep 20 09:00 AM
O'Malley Brendan M.SVP, General CounselSep 18 '23Buy3.803,00011,400187,421Sep 19 09:00 AM
Amoroso MichaelDirectorJun 20 '23Sale4.453381,504114,792Jun 21 04:05 PM